The US Food and Drug Administration (FDA) has approved Respicardia’s transvenous implantable neurostimulation system, remede, for moderate to severe central sleep apnea (CSA) in adults.
Remede is designed to activate the phrenic nerve and engage the diaphragm to restore natural breathing during sleep by creating negative pressure that moves air into the lungs.
As the system delivers automatic and continuous therapy throughout the night, it eliminates the need for external equipment.
